OmniCAR HER2 & EGFRvIII (Prescient Therapeutics)

N/A

Report date: 2025/01/26 16:59:18

Base Information

Drug NameOmniCAR HER2 & EGFRvIII (Prescient Therapeutics)

Drug Alias NameDual anti-HER2/anti-EGFRvIII CAR T-cell therapy (Prescient Therapeutics)CAR T-cell therapy (Prescient Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsEpidermal growth factor receptor variant III modulators

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrescient Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrescient Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A